Low plasma adiponectin concentration is associated with myocardial infarction in young individuals

Journal of Internal Medicine

Volumn 268, Issue 2, 2010, Pages 194-205

  Persson, J ^a,c   Lindberg, K ^b   Gustafsson, T P ^c   Eriksson, P ^c   Paulsson Berne, G ^c   Lundman, P ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

adiponectin; coronary heart disease; gene polymorphisms; genetics

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SMOKING;

ADIPONECTIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 77954322164     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02247.x     Document Type: Article

References (56)

1. Tunstall-Pedoe H, Vanuzzo D, Hobbs M et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000 355 : 688 700.
2. World Health Organization The global burden of disease - 2004 update. 2004.
3. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983 67 : 968 977.
4. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 : 937 952.
5. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002 13 : 51 9.
6. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009 53 : 577 584.
7. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007 101 : 27 39.
8. Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 2008 582 : 74 80.
9. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003 52 : 1779 1785.
10. Okamoto Y, Folco EJ, Minami M et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008 102 : 218 225.
11. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008 114 : 361 374.
12. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999 257 : 79 83.
13. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000 20 : 1595 1599.
14. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005 257 : 167 175.
15. Choi KM, Lee J, Lee KW et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 2004 61 : 75 80.
16. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003 361 : 226 228.
17. Kissebah AH, Sonnenberg GE, Myklebust J et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A 2000 97 : 14478 14483.
18. Vionnet N, Hani ElH, Dupont S et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000 67 : 1470 1480.
19. Patel S, Flyvbjerg A, Kozakova M et al. Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J 2008 29 : 386 393.
20. Hivert MF, Manning AK, McAteer JB et al. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes 2008 57 : 3353 3359.
21. Heid IM, Wagner SA, Gohlke H et al. Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes 2006 55 : 375 384.
22. Kondo H, Shimomura I, Matsukawa Y et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002 51 : 2325 2328.
23. Hoefle G, Muendlein A, Saely CH et al. The -11377 C > G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men. Thromb Haemost 2007 97 : 451 457.
24. Oguri M, Kato K, Yokoi K et al. Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome. Atherosclerosis 2009 206 : 486 493.
25. Qi L, Li T, Rimm E et al. The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes 2005 54 : 1607 1610.
26. Qi L, Doria A, Manson JE et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes 2006 55 : 1512 1516.
27. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003 23 : 85 9.
28. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004 291 : 1730 1737.
29. Pilz S, Maerz W, Weihrauch G et al. Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2006 364 : 251 255.
30. Sattar N, Wannamethee G, Sarwar N et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006 114 : 623 629.
31. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008 93 : 3357 3364.
32. Cavusoglu E, Ruwende C, Chopra V et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006 27 : 2300 2309.
33. Pilz S, Mangge H, Wellnitz B et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006 91 : 4277 4286.
34. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005 112 : 1756 1762.
35. Samnegard A, Silveira A, Lundman P et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005 258 : 411 419.
36. Carlson K. Lipoprotein fractionation. J Clin Pathol Suppl (Assoc Clin Pathol) 1973 5 : 32 7.
37. Bacci S, Menzaghi C, Ercolino T et al. The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care 2004 27 : 2015 2020.
38. Cheng KK, Lam KS, Wang Y et al. Adiponectin-induced eNOS activation and Nitric Oxide Production are Mediated by APPL1 in Endothelial Cells. Diabetes 2007 56 : 1387 1394.
39. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003 278 : 45021 45026.
40. Kobayashi H, Ouchi N, Kihara S et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004 94 : e27 31.
41. Gonon AT, Widegren U, Bulhak A et al. Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Cardiovasc Res 2008 78 : 116 122.
42. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007 92 : 571 576.
43. Nilsson PM, Engstrom G, Hedblad B et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006 26 : 2758 2762.
44. Kiris I, Tekin I, Yesildag A et al. Inverse relationship between adiponectin levels and subclinical carotid atherosclerosis in patients undergoing coronary artery bypass grafting. Int Heart J 2006 47 : 855 866.
45. Dekker JM, Funahashi T, Nijpels G et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008 93 : 1489 1496.
46. Hansen T, Ahlstrom H, Soderberg S et al. Visceral adipose tissue, adiponectin levels and insulin resistance are related to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly population. Atherosclerosis 2008 205 : 163 167.
47. Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infarction: a paradox or a paradigm? Eur Heart J 2006 27 : 2266 2268.
48. Yamauchi T, Nio Y, Maki T et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007 13 : 332 339.
49. Bjursell M, Ahnmark A, Bohlooly YM et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 2007 56 : 583 593.
50. Warodomwichit D, Shen J, Arnett DK et al. ADIPOQ polymorphisms, monounsaturated fatty acids, and obesity risk: the GOLDN study. Obesity (Silver Spring) 2009 17 : 510 517.
51. Kyriakou T, Collins LJ, Spencer-Jones NJ et al. Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity. J Hum Genet 2008 53 : 718 727.
52. Filippi E, Sentinelli F, Romeo S et al. The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age
53. Gable DR, Matin J, Whittall R et al. Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects. Ann Hum Genet 2007 71 : 453 466.
54. Yoshida T, Yajima K, Hibino T et al. Association of gene polymorphisms with myocardial infarction in individuals with different lipid profiles. Int J Mol Med 2007 20 : 581 590.
55. Koh KK, Quon MJ, Han SH et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009 204 : 483 490.
56. Kai T, Arima S, Taniyama Y, Nakabou M, Kanamasa K. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. Clin Exp Hypertens 2008 30 : 530 540.